2016
DOI: 10.1128/aac.00727-16
|View full text |Cite
|
Sign up to set email alerts
|

Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection

Abstract: g Severely burned patients have altered drug pharmacokinetics (PKs), but it is unclear how different they are from those in other critically ill patient groups. The aim of the present study was to compare the population pharmacokinetics of micafungin in the plasma and burn eschar of severely burned patients with those of micafungin in the plasma and peritoneal fluid of postsurgical critically ill patients with intra-abdominal infection. Fifteen burn patients were compared with 10 patients with intra-abdominal … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
12
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 23 publications
(14 citation statements)
references
References 31 publications
2
12
0
Order By: Relevance
“…These results could correlate with, and also support those that we previously obtained in the first study [ 2 ] published on the pharmacokinetics (PK) of micafungin in plasma and burn eschar tissue in critically ill patients with severe burn injuries, which were compared with the PK of micafungin in patients with intra-abdominal infections [ 3 ]. In our study, 15 burn patients were compared with ten patients with intra-abdominal infection; all patients were treated with 100 to 150 mg/day of micafungin.…”
supporting
confidence: 89%
“…These results could correlate with, and also support those that we previously obtained in the first study [ 2 ] published on the pharmacokinetics (PK) of micafungin in plasma and burn eschar tissue in critically ill patients with severe burn injuries, which were compared with the PK of micafungin in patients with intra-abdominal infections [ 3 ]. In our study, 15 burn patients were compared with ten patients with intra-abdominal infection; all patients were treated with 100 to 150 mg/day of micafungin.…”
supporting
confidence: 89%
“…The probability of target attainment was estimated based on target AUC 0–24 h /MIC ratios of 285 and 3000 for C. parapsilosis and C. non - parapsilosis , respectively. By a single dose of 100 mg, targets were achieved for strains with low MICs of ≤0.008 and ≤0.064, respectively [ 385 ].…”
Section: Micafunginmentioning
confidence: 99%
“…The plasma concentrations of micafungin and covariates influencing the concentration have been investigated in 15 population PK models (see Table 2 for details) [ 38 , 41 , 45 , 47 , 52 , 53 , 55 , 58 65 ]. In all cases, the plasma concentration was best described using a two-compartment model; additional compartments were used to explain tissue concentrations in two studies [ 41 , 47 ]. In the majority of the models, weight was incorporated to explain variability in systemic CL, and, in approximately half of the models, weight was also able to explain variability in V d of the central compartment.…”
Section: Pharmacokinetics (Pk) In Adults Patientsmentioning
confidence: 99%
“…and C. parapsilosis species, with MIC values up to 0.008 and 0.064 mg/L, respectively. A licensed dose of 200 mg was found to be sufficient to achieve the European Committee on Antimicrobial Susceptibility Testing (EUCAST) susceptibility target for C. albicans (0.016 mg/L), but not for C. glabrata (0.03 mg/L) [ 41 ].…”
Section: Special Populationsmentioning
confidence: 99%